After reconstitution, the product is injected into the deep dermis or subcutaneous tissue, where PLLA microparticles act as a biostimulatory scaffold. Over time, these particles activate fibroblasts, promoting the formation of new collagen fibers. As the PLLA is slowly and safely biodegraded, the newly formed collagen provides sustained volume restoration and structural support to the skin.
Lanluma V is designed for use on both the face and body and is particularly suitable for patients with moderate to severe volume loss who seek natural rejuvenation without abrupt volumising effects.
This product is a CE-marked medical device and is intended exclusively for professional use by trained healthcare practitioners, in accordance with EU and German medical device regulations.
Lanluma V provides a progressive and long-lasting rejuvenation effect by addressing the underlying causes of ageing-related volume loss. It is indicated for:
- Deep wrinkles and folds
- Loss of facial or body volume
- Skin laxity and reduced firmness
- Age-related structural changes
Typical treatment areas include the cheeks, temples, jawline, chin, as well as selected body areas requiring volume restoration and skin tightening.
With course-based treatment, patients may experience:
- Gradual restoration of lost volume
- Improved skin firmness and density
- Smoother skin texture and reduced depth of wrinkles
- Natural-looking rejuvenation without overcorrection
- Long-lasting results due to collagen neogenesis
Results develop progressively over several weeks as new collagen is formed. Depending on the individual treatment protocol and patient characteristics, the effects may last up to 18–24 months.
Treatment usually consists of 1–3 sessions, spaced several weeks apart. The exact protocol should be determined by the treating medical professional following patient assessment.